0001209191-20-032214.txt : 20200526 0001209191-20-032214.hdr.sgml : 20200526 20200526210441 ACCESSION NUMBER: 0001209191-20-032214 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200521 FILED AS OF DATE: 20200526 DATE AS OF CHANGE: 20200526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cappel Markus J. CENTRAL INDEX KEY: 0001422995 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 20912546 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ChemoCentryx, Inc. CENTRAL INDEX KEY: 0001340652 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943254365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-210-2900 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-21 0 0001340652 ChemoCentryx, Inc. CCXI 0001422995 Cappel Markus J. C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 0 1 0 0 Chief Bus. Officer & Treasurer Common Stock 2020-05-21 4 M 0 2800 6.62 A 79047 D Common Stock 2020-05-21 4 S 0 2800 59.995 D 76247 D Common Stock 2020-05-22 4 M 0 40867 6.62 A 117114 D Common Stock 2020-05-22 4 S 0 40867 60.0613 D 76247 D Common Stock 2020-05-26 4 M 0 19612 6.62 A 95859 D Common Stock 2020-05-26 4 S 0 19612 60.3418 D 76247 D Stock Option (right to buy) 6.62 2020-05-21 4 M 0 2800 D 2027-02-28 Common Stock 2800 84854 D Stock Option (right to buy) 6.62 2020-05-22 4 M 0 40867 D 2027-02-28 Common Stock 40867 43987 D Stock Option (right to buy) 6.62 2020-05-26 4 M 0 19612 D 2027-02-28 Common Stock 19612 24375 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $59.99 to $60.05 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $59.99 to $60.44 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $59.99 to $60.89 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. As of May 21, 2020, and prior to this transaction, the exercised options were fully vested. Not applicable. /s/ Susan M. Kanaya, as Attorney-in-Fact 2020-05-26